{
    "root": "25021c88-95e1-42f0-b895-921526b90642",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SOLIRIS",
    "value": "20250307",
    "ingredients": [
        {
            "name": "ECULIZUMAB",
            "code": "A3ULP0F556"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM",
            "code": "3980JIH2SW"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM",
            "code": "GR686LBA74"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "soliris complement inhibitor indicated : treatment patients paroxysmal nocturnal hemoglobinuria ( pnh ) reduce hemolysis . ( 1.1 ) treatment patients atypical hemolytic uremic syndrome ( ahus ) inhibit complement-mediated thrombotic microangiopathy . ( 1.2 ) limitation soliris indicated treatment patients shiga toxin e. coli related hemolytic uremic syndrome ( stec-hus ) . treatment generalized myasthenia gravis ( gmg ) adult pediatric patients six years age older anti-acetylcholine receptor ( achr ) antibody positive . ( 1.3 ) treatment neuromyelitis optica spectrum disorder ( nmosd ) adult patients anti-aquaporin-4 ( aqp4 ) antibody positive . ( 1.4 )",
    "contraindications": "intravenous infusion ; recommended : pnh : ( 2.2 ) ahus , gmg , nmosd adults : ( 2.3 ) ahus gmg pediatric patients : ( 2.4 )",
    "warningsAndPrecautions": "soliris ( eculizumab ) injection sterile , preservative-free , clear , colorless solution supplied one 300 mg/30 ml ( 10 mg/ml ) single-dose vial per carton ( ndc 25682-001-01 ) .",
    "adverseReactions": "soliris contraindicated initiation patients unresolved serious neisseria meningitidis infection [ ( 5.1 ) ] .",
    "indications_original": "SOLIRIS is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive. ( 1.3 ) the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.4 )",
    "contraindications_original": "For intravenous infusion only; recommended dosage for: PNH: ( 2.2 ) aHUS, gMG, and NMOSD in adults: ( 2.3 ) aHUS and gMG in pediatric patients: ( 2.4 )",
    "warningsAndPrecautions_original": "SOLIRIS (eculizumab) injection is a sterile, preservative-free, clear, colorless solution supplied as one 300 mg/30 mL (10 mg/mL) single-dose vial per carton (NDC 25682-001-01).",
    "adverseReactions_original": "SOLIRIS is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection [see Warnings and Precautions (5.1)]."
}